PepSight
GROWTH HORMONE RELEASING

CJC-1295 (with DAC)

CJC-1295 (with DAC) is a growth hormone releasing peptide used in evidence-based, physician-supervised protocols. Use when consistent elevated GH levels are preferred over pulsatile pattern (e.g., tissue repair, fat loss, anti-aging).

What is CJC-1295 (with DAC)?

Same GHRH analogue but with Drug Affinity Complex (DAC) that binds albumin, extending half-life to 6-8 days. Produces sustained GH elevation vs. pulsatile pattern of No-DAC version.

Uses & clinical decision logic

Use when consistent elevated GH levels are preferred over pulsatile pattern (e.g., tissue repair, fat loss, anti-aging). Twice-weekly dosing preferred.

CJC-1295 (with DAC) dosage & administration

Vial sizeBAC waterDosing rangeUnits / doseFrequencyRoute
5mg2mL1-2mg40-80 units1-2x/weekSubQ

Safety & contraindications

Monitor for GH bleed (elevated IGF-1, water retention, joint aches) — reduce dose if side effects emerge. Active cancer contraindication.

Stacking & combinations

Can combine with Ipamorelin on non-injection days; or use standalone for long-acting GH elevation.

Related peptides

Frequently asked questions

What is CJC-1295 (with DAC) used for?

Use when consistent elevated GH levels are preferred over pulsatile pattern (e.g., tissue repair, fat loss, anti-aging). Twice-weekly dosing preferred.

What is the typical CJC-1295 (with DAC) dosage?

Common dosing ranges from 1-2mg (1-2x/week, SubQ). Exact dosing is individualized and set by a licensed physician.

How is CJC-1295 (with DAC) administered?

CJC-1295 (with DAC) is typically administered via SubQ.

What are the contraindications for CJC-1295 (with DAC)?

Monitor for GH bleed (elevated IGF-1, water retention, joint aches) — reduce dose if side effects emerge. Active cancer contraindication.

Considering CJC-1295 (with DAC)?

Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.

Build your protocol →

This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.